Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: David Cathcart who wrote (6022)	11/24/1998 8:39:00 AM
From: Russian Bear	Read Replies (2) \| Respond to of 9719

<<Richard Dean Bagnell pointed out on the Yahoo MOGN thread that in one month the reported tumor shrinkage of the phase I pancreatic patient went from >50% to >70%. This was between the fifth and sixth months of treatment. His point was that perhaps the drug works better as the tumor gets smaller. It is interesting that the tumor shrunk 40% in that one month span.>> David, It is my understanding (perhaps mistaken) that an "objective partial response" (that which was claimed for one MGI-114 PI patient in the 15 October 1998 press release) indicates tumor shrinkage by 50% or greater. The newer figure of >70% may be, in fact, merely a further clarification of the extent of the objective partial response observed earlier. (In essence, >70 is also >50.) I am not implying that I know this to be the case, by any means. It is by no means inconceivable that this pancreatic cancer patient did, indeed, experience a tumor regression of 40% over one month. However, this is not necessarily the case, according to the way that I read the two press releases in question. I would be absolutely ecstatic, by the way, if anyone were to demonstrate that I am completely wrong about this, and that this tumor did, indeed, shrink 40% in month 5 of treatment. Best regards, RB